Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577337 | 0.95 | TSHR (0.56) | ALDH1A1PTBP1TSHRKMT2APOLB | |
| SCHEMBL5577471 | 0.92 | MEN1 (0.58) | ALDH1A1PTBP1TSHRKMT2APOLB | |
| SCHEMBL5577355 | 0.91 | CCR5 (0.54) | ALDH1A1PTBP1TSHRKMT2APOLB | |
| SCHEMBL5577541 | 0.90 | PTBP1 (0.50) | ALDH1A1PTBP1TSHRKMT2APOLB | |
| SCHEMBL5577498 | 0.86 | DRD2 (0.53) | ALDH1A1PTBP1KMT2APOLBMEN1 | |
| SCHEMBL5577516 | 0.85 | ALDH1A1 (0.66) | ALDH1A1KMT2APOLBCCR3GAA | |
| SCHEMBL5577770 | 0.84 | MEN1 (0.53) | ALDH1A1PTBP1TSHRKMT2APOLB | |
| SCHEMBL5577301 | 0.83 | ALDH1A1 (0.51) | ALDH1A1PTBP1KMT2APOLBMEN1 | |
| SCHEMBL5577635 | 0.83 | TSHR (0.71) | ALDH1A1TSHRKMT2AMEN1EPHX2 | |
| SCHEMBL5577613 | 0.83 | MEN1 (0.53) | ALDH1A1PTBP1TSHRKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | ALDH1A1 1147/4885PTBP1 1360/4885TSHR 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.